Ligand completes USD 739 million XOMA Royalty acquisition at USD 39 a share - LGND News | RalliesLigand completes USD 739 million XOMA Royalty acquisition at USD 39 a share
L
LGND• Ligand closes XOMA Royalty acquisition
- Ligand Pharmaceuticals completed its acquisition of XOMA Royalty for USD 39 per share in cash, valuing the deal at about USD 739 million.
- XOMA Royalty shareholders also received one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation.
- The deal adds seven commercial royalty products and more than 100 development and commercial-stage assets, taking Ligand’s portfolio above 200 assets.
- Ligand expects the transaction to be immediately accretive, adding about USD 0.5 to 2026 adjusted EPS and USD 1.5 to 2027 adjusted EPS.
- XOMA Royalty shares ceased trading on the Nasdaq Global Market following the closing.
